Annexon Inc (ANNX)
4.87
+0.14
(+2.96%)
USD |
NASDAQ |
May 08, 16:00
4.87
0.00 (0.00%)
After-Hours: 16:21
Annexon Research and Development Expense (Quarterly): 23.27M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 23.27M |
| September 30, 2023 | 27.89M |
| June 30, 2023 | 30.25M |
| March 31, 2023 | 32.34M |
| December 31, 2022 | 28.54M |
| September 30, 2022 | 27.86M |
| June 30, 2022 | 29.11M |
| March 31, 2022 | 27.00M |
| December 31, 2021 | 27.22M |
| September 30, 2021 | 27.58M |
| Date | Value |
|---|---|
| June 30, 2021 | 24.57M |
| March 31, 2021 | 20.70M |
| December 31, 2020 | 17.99M |
| September 30, 2020 | 11.78M |
| June 30, 2020 | 9.287M |
| March 31, 2020 | 10.22M |
| December 31, 2019 | 6.795M |
| September 30, 2019 | 7.089M |
| June 30, 2019 | 5.987M |
| March 31, 2019 | 4.653M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
5.987M
Minimum
Jun 2019
32.34M
Maximum
Mar 2023
20.81M
Average
24.57M
Median
Jun 2021
Research and Development Expense (Quarterly) Benchmarks
| Trxade Health Inc | 0.3665M |
| P3 Health Partners Inc | -- |
| Arrowhead Pharmaceuticals Inc | 116.49M |
| Insmed Inc | 137.03M |
| Heron Therapeutics Inc | 10.95M |